AMERITRADE
DATEK
Discover Brokerage
DLJDirect
E-Trade
Schwab




To receive immediate notification of research updates, enter your e-mail address here (ex: name@domain.com):


  CUBIST PHARMACEUTICALS, INC.
Cubist Pharmaceuticals is an emerging pharmaceutical company that we believe represents a promising investment opportunity based on its combination of late-stage drug development, and genomics and assay development technologies, all in the area of anti-infectives. CBST has just initiated the first of two Phase III trials, and an open-label Phase II trial, on its novel antibiotic daptomycin, which has been shown to be effective against all gram-positive organisms, including many of the antibiotic-resistant, so-called "Super Bugs"that are becoming increasing prevalent in our healthcare system today. CBST is also using proprietary technology it calls VITA, in partnership with major pharmaceutical companies, to identify new anti-infective targets and drug candidates. CBST recently announced a three-year collaboration with Novartis, in a deal worth up to $33 million based upon achievements of certain milestones.


SMALLCAPS RESEARCH